Cantel Medical Corp. (CMN) Director Ann E. Berman Sells 1,453 Shares
Cantel Medical Corp. (NYSE:CMN) Director Ann E. Berman sold 1,453 shares of the company’s stock in a transaction on Friday, September 30th. The stock was sold at an average price of $77.56, for a total value of $112,694.68. Following the transaction, the director now directly owns 5,424 shares in the company, valued at approximately $420,685.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Cantel Medical Corp. (NYSE:CMN) opened at 78.46 on Thursday. The firm’s 50 day moving average is $76.84 and its 200 day moving average is $70.89. Cantel Medical Corp. has a 12 month low of $52.23 and a 12 month high of $81.63. The company has a market cap of $3.25 billion, a PE ratio of 54.56 and a beta of 1.59.
Cantel Medical Corp. (NYSE:CMN) last announced its earnings results on Thursday, September 29th. The company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.37 by $0.11. Cantel Medical Corp. had a net margin of 9.02% and a return on equity of 16.70%. The company had revenue of $179 million for the quarter. During the same period in the prior year, the business posted $0.39 earnings per share. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. On average, equities analysts predict that Cantel Medical Corp. will post $1.98 earnings per share for the current year.
Several research analysts have issued reports on the company. Benchmark Co. set a $83.00 price objective on Cantel Medical Corp. and gave the stock a “buy” rating in a report on Saturday, October 1st. Needham & Company LLC initiated coverage on shares of Cantel Medical Corp. in a research report on Wednesday, August 24th. They set a “hold” rating for the company.
A number of hedge funds and other institutional investors have recently made changes to their positions in CMN. State Street Corp boosted its position in shares of Cantel Medical Corp. by 1.4% in the first quarter. State Street Corp now owns 698,437 shares of the company’s stock worth $49,838,000 after buying an additional 9,417 shares during the period. UBS Group AG boosted its position in shares of Cantel Medical Corp. by 2.6% in the first quarter. UBS Group AG now owns 52,630 shares of the company’s stock worth $3,756,000 after buying an additional 1,348 shares during the period. BlackRock Group LTD boosted its position in shares of Cantel Medical Corp. by 9.5% in the first quarter. BlackRock Group LTD now owns 42,830 shares of the company’s stock worth $3,056,000 after buying an additional 3,701 shares during the period. Bogle Investment Management L P DE purchased a new position in shares of Cantel Medical Corp. during the first quarter worth about $228,000. Finally, Advisors Asset Management Inc. purchased a new position in shares of Cantel Medical Corp. during the second quarter worth about $6,672,000. 81.61% of the stock is currently owned by institutional investors and hedge funds.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.